URGN Company Profile and Key Details
NASDAQ : URGN
UroGen Pharma
$43.25
-0.7-1.59%
Open: 4:00 PM60.56
BESG ScoreESG Rating
Price Chart
Stock Price Today
UroGen Pharma Ltd. (URGN) stock declined over -1.59%, trading at $43.25 on NASDAQ, down from the previous close of $43.95. The stock opened at $43.73, fluctuating between $43.16 and $44.25 in the recent session.
Stock Snapshot
43.95
Prev. Close
2.11B
Market Cap
43.16
Day Low
-21.84
P/E Ratio
-1.98
EPS (TTM)
-2.12
Cash Flow per Share
43.73
Open
48.72M
Number of Shares
44.25
Day High
80.04%
Free Float in %
-1.8
Book Value
639.74K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | 44.00 | 44.25 | 43.15 | 43.25 | 639.74K |
| Sep 17, 2026 | 44.82 | 45.33 | 43.15 | 43.95 | 681.4K |
| Sep 16, 2026 | 42.07 | 43.72 | 42.07 | 43.49 | 994K |
| Sep 15, 2026 | 43.25 | 43.25 | 41.09 | 41.74 | 537.1K |
| Sep 14, 2026 | 42.36 | 43.72 | 41.65 | 42.64 | 505.83K |
| Sep 11, 2026 | 43.13 | 43.61 | 41.60 | 42.31 | 676.5K |
| Sep 10, 2026 | 44.25 | 44.48 | 41.85 | 42.24 | 688.66K |
| Sep 09, 2026 | 43.82 | 47.06 | 43.77 | 45.00 | 1.02M |
| Sep 08, 2026 | 43.24 | 44.72 | 42.50 | 43.82 | 418.45K |
| Sep 04, 2026 | 44.54 | 45.10 | 43.50 | 44.09 | 340.24K |
| Sep 03, 2026 | 44.37 | 45.63 | 43.45 | 44.88 | 445.3K |
| Sep 02, 2026 | 44.01 | 45.88 | 43.49 | 44.42 | 473.4K |
| Sep 01, 2026 | 42.59 | 43.56 | 42.52 | 43.39 | 584.19K |
| Aug 31, 2026 | 43.17 | 44.86 | 42.00 | 43.09 | 749K |
| Aug 28, 2026 | 45.09 | 45.54 | 43.39 | 43.62 | 580.05K |
| Aug 27, 2026 | 46.13 | 46.51 | 45.29 | 45.50 | 559.77K |
| Aug 26, 2026 | 46.00 | 46.64 | 45.36 | 45.94 | 620.21K |
| Aug 25, 2026 | 46.65 | 47.17 | 45.67 | 46.36 | 570.16K |
| Aug 24, 2026 | 46.52 | 47.05 | 45.27 | 46.16 | 849.67K |
| Aug 21, 2026 | 47.13 | 47.28 | 45.60 | 46.86 | 755.5K |
Contact Details
About Company
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Company Information
| Employees | 300 |
| Beta | 1.58 |
| Sales or Revenue | $82.71M |
| 5Y Sales Change% | 39.064% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-5.45-0.55%
argenx SE$990.32REGN-4.6-0.58%
Regeneron Pharmaceuticals, Inc.$784.85MDGL-2.88-0.54%
Madrigal Pharmaceuticals, Inc.$531.52VRTX-8.00008-1.55%
Vertex Pharmaceuticals Incorporated$508.34UTHR-2.64-0.53%
United Therapeutics Corporation$494.63ONC-2.62-0.74%
BeOne Medicines AG$350.84KRYS-2.08-0.61%
Krystal Biotech, Inc.$336.67KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX-11.52-3.71%
Praxis Precision Medicines, Inc.$298.95LGND-1.21-0.43%
Ligand Pharmaceuticals Incorporated$283.49Company Overview
UroGen Pharma Ltd. (NASDAQ:URGN) closed at $43.25 USD, losing -$0.70 (-1.59%) from the previous close of $43.95. The stock is currently mid-range between its 52-week high and low $15.86 and $50.81. With a market capitalization of about $2.11 billion, UroGen Pharma Ltd. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 825.22 thousand shares, in line with its 52-week average. Headquartered in Princeton, NJ, UroGen Pharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Elizabeth Barrett, the company employs approximately 300 people and listed since May 04, 2017. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 1.62%, SMA50 -1.01%, SMA200 16.58%). The stock’s 14-day RSI is 51.02 (neutral), while the ATR of 1.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.4% below its high and over 519.3% above its low. Average 10-day trading volume of 674.75 thousand shares is below the 3-month average of 801.06 thousand, indicating normal recent market interest.
Valuation Metrics
UroGen Pharma Ltd. trades at a P/E ratio of -21.84, slightly below the S&P 500 average, with a price-to-sales ratio of 11.16 and a price-to-book ratio of -16.46 indicating negative book value, which may reflect financial stress. The P/FCF stands at -13.24, also below market averages.
Dividend & Fair Value
UroGen Pharma Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$30.06. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
UroGen Pharma Ltd. generated EPS of -$3.46 over the past year. Five-year average earnings growth is 10.39%. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.50. Next year's EPS is expected at $27.33. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $25.00. The high target offers 38.73% upside. The low target suggests -42.2% downside. The mean target is $39.21. This offers -9.34% upside. UroGen Pharma Ltd. earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by 5.66%. The prior quarter beat by -2.58%. Over the last six quarters, Apple has recorded several small beats. These include 10.84% in May 12, 2025.
Shareholding & Insider Activity
UroGen Pharma Ltd. has 48.88 million shares outstanding. The public float is 43.35 million shares, elevated short interest at 9.61% of float. This equals 4.59 million shares. The short ratio is 6.04 days. Institutional investors hold 103.94% of the float. Insiders own 3.48%. ProQuest Investments IV, L.P. holds 1.24 million shares, Barrett Elizabeth A. has 300.98 thousand shares and Schoenberg Mark has 59.88 thousand shares. Over the past six months, insider transactions show net selling. They sold 98.29 thousand shares across 7 transactions.
Financial & Profitability Overview
On valuation metrics, UroGen Pharma trades at a P/E of -21.84, P/S of 11.16 and P/B of -16.46. The current ratio is 3.80 and quick ratio is 3.41. Operationally, the company’s inventory turnover is 0.70 and cash conversion cycle is -152.75 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.48, supported by a cash flow-to-debt ratio of -0.81.
Quarterly Financial Highlights
The company ended the quarter with $137.79M in cash and short-term investments, a total debt of $100.21M, and net debt of $4.39M. Total assets were $178.31M, with equity of - $65.21M. Financials further reflected weakness, with operating cash flow of - $76.38M, free cash flow of - $76.57M, and capital expenditures of - $194.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that UroGen Pharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.73%, with price expected at $40.34 by October 02, 2026, within a range of $38.59 to $42.17 3-Month Outlook: Projected rise of 15.88%, reaching $50.12 by December 17, 2026, with a range of $45.20 to $53.82. 1-Year Outlook: Projected gain of 16.95%, with price at $50.58 by September 17, 2027, within a range of $48.10 to $53.16.
Key Takeaways
UroGen Pharma Ltd. (NASDAQ:URGN) shares are down -17.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows UroGen Pharma Ltd. trading at a premium to the broader market with a P/E of -21.84. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $39.09, suggesting -9.62% downside. Our AI forecast model points to short-term weakness (-6.73% over two weeks), a medium-term rise (15.88% over three months), and a longer-term gain (16.95% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current UroGen Pharma Ltd. (URGN) stock price?
UroGen Pharma Ltd. (NASDAQ: URGN) stock price is $43.25 in the last trading session. During the trading session, URGN stock reached the peak price of $44.25 while $43.16 was the lowest point it dropped to. The percentage change in URGN stock occurred in the recent session was -1.59% while the dollar amount for the price change in URGN stock was - $0.70.
URGN's industry and sector of operation?
The NASDAQ listed URGN is part of Biotechnology industry that operates in the broader Healthcare sector. UroGen Pharma Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of URGN?
Mr. Jason Drew Smith
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Marina Konorty
Executive Vice President of R&D and Technical Operations
Ms. Elizabeth A. Barrett
Pres, Chief Executive Officer & Director
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality
Mr. Dong Kim
Chief Financial Officer
Eric Van Zanten
Senior Director of Communications
Dr. Sari Prutchi-Sagiv Ph.D.
Marketing Director
Mr. Jeffrey Bova M.B.A.
Chief Commercial Officer
Dr. Mark P. Schoenberg M.D.
Chief Medical Officer
Vincent I. Perrone
Senior Director of Investor Relations
Mr. Eric Van Zanten
Vice President of Investor & PR
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Marina Konorty
Executive Vice President of R&D and Technical Operations
Ms. Elizabeth A. Barrett
Pres, Chief Executive Officer & Director
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality
Mr. Dong Kim
Chief Financial Officer
Eric Van Zanten
Senior Director of Communications
Dr. Sari Prutchi-Sagiv Ph.D.
Marketing Director
Mr. Jeffrey Bova M.B.A.
Chief Commercial Officer
Dr. Mark P. Schoenberg M.D.
Chief Medical Officer
Vincent I. Perrone
Senior Director of Investor Relations
Mr. Eric Van Zanten
Vice President of Investor & PR
How URGN did perform over past 52-week?
URGN's closing price is 172.7% higher than its 52-week low of $15.86 where as its distance from 52-week high of $50.81 is -14.88%.
How many employees does URGN have?
Number of URGN employees currently stands at 300.
Link for URGN official website?
Official Website of URGN is: https://www.urogen.com
How do I contact URGN?
URGN could be contacted at phone 646 768 9780 and can also be accessed through its website. URGN operates from 400 Alexander Park Drive, Princeton, NJ 08540, United States.
How many shares of URGN are traded daily?
URGN stock volume for the day was 639.74K shares. The average number of URGN shares traded daily for last 3 months was 825.22K.
What is the market cap of URGN currently?
The market value of URGN currently stands at $2.11B with its latest stock price at $43.25 and 48.72M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep